View Item 

Show simple item record

Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2
dc.contributor.authorGeller, James I.en_US
dc.contributor.authorEhrlich, Peter F.en_US
dc.contributor.authorCost, Nicholas G.en_US
dc.contributor.authorKhanna, Geetikaen_US
dc.contributor.authorMullen, Elizabeth A.en_US
dc.contributor.authorGratias, Eric J.en_US
dc.contributor.authorNaranjo, Arleneen_US
dc.contributor.authorDome, Jeffrey S.en_US
dc.contributor.authorPerlman, Elizabeth J.en_US
dc.date.accessioned2015-07-01T20:55:57Z
dc.date.available2016-08-08T16:18:39Zen
dc.date.issued2015-07-15en_US
dc.identifier.citationGeller, James I.; Ehrlich, Peter F.; Cost, Nicholas G.; Khanna, Geetika; Mullen, Elizabeth A.; Gratias, Eric J.; Naranjo, Arlene; Dome, Jeffrey S.; Perlman, Elizabeth J. (2015). "Characterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2." Cancer 121(14): 2457-2464.en_US
dc.identifier.issn0008-543Xen_US
dc.identifier.issn1097-0142en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/111918
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherpediatricen_US
dc.subject.otheradolescenten_US
dc.subject.otherlymph nodeen_US
dc.subject.othertranslocation renal cell carcinomaen_US
dc.titleCharacterization of adolescent and pediatric renal cell carcinoma: A report from the Children's Oncology Group study AREN03B2en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbsecondlevelPublic Healthen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/111918/1/cncr29368.pdf
dc.identifier.doi10.1002/cncr.29368en_US
dc.identifier.sourceCanceren_US
dc.identifier.citedreferenceChowdhury T, Prichard‐Jones K, Sebire NJ, et al. Persistent complete response after single‐agent sunitinib treatment in a case of TFE translocation positive relapsed metastatic pediatric renal cell carcinoma. J Pediatr Hematol Oncol. 2013; 35: e1 ‐ e3.en_US
dc.identifier.citedreferenceArnoux V, Long JA, Fiard G, et al. Xp11.2 translocation renal carcinoma in adults over 50 years of age: about 4 cases [in French]. Prog Urol. 2012; 22: 932 ‐ 937.en_US
dc.identifier.citedreferenceGhoneim TP, Ouzzane A, Leroy X, et al. Renal cell carcinoma of patients younger than 40 years old [in French]. Prog Urol. 2012; 22: 93 ‐ 99.en_US
dc.identifier.citedreferenceHou MM, Hsieh JJ, Chang NJ, et al. Response to sorafenib in a patient with metastatic Xp11 translocation renal cell carcinoma. Clin Drug Invest. 2010; 30: 799 ‐ 804.en_US
dc.identifier.citedreferencePwint TP, Macaulay V, Roberts IS, et al. An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib. Urol Oncol. 2011; 29: 821 ‐ 824.en_US
dc.identifier.citedreferenceChoueiri TK, Mosquera JM, Hirsch MS. A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib. Clin Genitourin Cancer. 2009; 7: E93 ‐ E94.en_US
dc.identifier.citedreferenceMalouf GG, Camparo P, Molinie V, et al. Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors. J Urol. 2011; 185: 24 ‐ 29.en_US
dc.identifier.citedreferenceAoyagi T, Shinohara N, Kubota‐Chikai K, et al. Long‐term survival in a patient with node‐positive adult‐onset Xp11.2 translocation renal cell carcinoma. Urol Int. 2011; 86: 487 ‐ 490.en_US
dc.identifier.citedreferenceGeller J, Mullen E, Khanna G, et al. Epidemiology and characterization of pediatric and adolescent renal cell carcinoma: a report from the Children's Oncology Group Study AREN 03B2. BJU Int. 2012; 110 ( suppl 2 ): 18.en_US
dc.identifier.citedreferenceMalouf GG, Camparo P, Oudard S, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol. 2010; 21: 1834 ‐ 1838.en_US
dc.identifier.citedreferenceParikh J, Coleman T, Messias N, et al. Temsirolimus in the treatment of renal cell carcinoma associated with Xp11.2 translocation/TFE gene fusion proteins: a case report and review of literature. Rare Tumors. 2009; 1: e53.en_US
dc.identifier.citedreferenceLiu YC, Chang PM, Liu CY, et al. Sunitinib‐induced nephrotic syndrome in association with drug response in a patient with Xp11.2 translocation renal cell carcinoma. Jpn J Clin Oncol. 2011; 41: 1277 ‐ 1281.en_US
dc.identifier.citedreferenceNumakura K, Tsuchiya N, Yuasa T, et al. A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib. Int J Clin Oncol. 2011; 16: 577 ‐ 580.en_US
dc.identifier.citedreferenceLae M, Argani P, Olshen AB, et al. Global gene expression profiles of renal carcinomas with Xp11 translocations (TFE3 gene fusions) suggest a closer relationship to alveolar soft part sarcomas than adult type renal cell carcinomas [abstract]. Mod Pathol. 2004; 17 ( suppl 1 ): 163A.en_US
dc.identifier.citedreferenceNanus DM, Garino A, Milowsky MI, et al. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer. 2004; 101: 1545 ‐ 1551.en_US
dc.identifier.citedreferenceHaas NB, Lin X, Manola J, et al. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol. 2012; 29: 761 ‐ 767.en_US
dc.identifier.citedreferenceStrouse JJ, Spevak M, Mack AK, et al. Significant responses to platinum‐based chemotherapy in renal medullary carcinoma. Pediatr Blood Cancer. 2005; 44: 407 ‐ 411.en_US
dc.identifier.citedreferenceRonnen EA, Kondagunta GV, Motzer RJ. Medullary renal cell carcinoma and response to therapy with bortezomib. J Clin Oncol. 2006; 24: e14.en_US
dc.identifier.citedreferenceDowney RT, Dillman JR, Ladino‐Torres MF, et al. CT and MRI appearances and radiologic staging of pediatric renal cell carcinoma. Pediatr Radiol. 2012; 42: 410 ‐ 417.en_US
dc.identifier.citedreferenceBruder E, Passera O, Harms D, et al. Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol. 2004; 28: 1117 ‐ 1132.en_US
dc.identifier.citedreferenceJewett MA, Mattar K, Basiuk J, et al. Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol. 2011; 60: 39 ‐ 44.en_US
dc.identifier.citedreferenceEhrlich PF, Ritchey ML, Hamilton TE, et al. Quality assessment for Wilms' tumor: a report from the National Wilms' Tumor Study‐5. J Pediatr Surg. 2005; 40: 208 ‐ 212; discussion 212‐213.en_US
dc.identifier.citedreferenceVolpe A, Cadeddu JA, Cestari A, et al. Contemporary management of small renal masses. Eur Urol. 2011; 60: 501 ‐ 515.en_US
dc.identifier.citedreferenceCook A, Lorenzo AJ, Salle JL, et al. Pediatric renal cell carcinoma: single institution 25‐year case series and initial experience with partial nephrectomy. J Urol. 2006; 175: 1456 ‐ 1460; discussion 1460.en_US
dc.identifier.citedreferenceCost NG, Geller JI, DeFoor WR, et al. A robotic‐assisted laparoscopic approach for pediatric renal cell carcinoma allows for both nephron‐sparing surgery and extended lymph node dissection. J Pediatr Surg. 2012; 47: 1946 ‐ 1950.en_US
dc.identifier.citedreferenceIndolfi P, Bisogno G, Cecchetto G, et al. Local lymph node involvement in pediatric renal cell carcinoma: a report from the Italian TREP project. Pediatr Blood Cancer. 2008; 51: 475 ‐ 478.en_US
dc.identifier.citedreferenceGeller JI, Dome JS. Local lymph node involvement does not predict poor outcome in pediatric renal cell carcinoma. Cancer. 2004; 101: 1575 ‐ 1583.en_US
dc.identifier.citedreferenceSpreafico F, Collini P, Terenziani M, et al. Renal cell carcinoma in children and adolescents. Expert Rev Anticancer Ther. 2010; 10: 1967 ‐ 1978.en_US
dc.identifier.citedreferenceGeller JI, Argani P, Adeniran A, et al. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer. 2008; 112: 1607 ‐ 1616.en_US
dc.identifier.citedreferenceChoueiri TK, Lim ZD, Hirsch MS, et al. Vascular endothelial growth factor‐targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer. 2010; 116: 5219 ‐ 5225.en_US
dc.identifier.citedreferencePantuck AJ, Zisman A, Dorey F, et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer. 2003; 97: 2995 ‐ 3002.en_US
dc.identifier.citedreferenceGow KW, Barnhart DC, Hamilton TE, et al. Primary nephrectomy and intraoperative tumor spill: report from the Children's Oncology Group (COG) renal tumors committee. J Pediatr Surg. 2013; 48: 34 ‐ 38.en_US
dc.identifier.citedreferenceSelle B, Furtwangler R, Graf N, et al. Population‐based study of renal cell carcinoma in children in Germany, 1980‐2005: more frequently localized tumors and underlying disorders compared with adult counterparts. Cancer. 2006; 107: 2906 ‐ 2914.en_US
dc.identifier.citedreferenceZhong M, De Angelo P, Osborne L, et al. Translocation renal cell carcinomas in adults: a single‐institution experience. Am J Surg Pathol. 2012; 36: 654 ‐ 662.en_US
dc.identifier.citedreferenceKauffman E, Gupta G, Cecchi F, et al. Characterization of the Akt‐mTOR pathway in TFE3‐fusion renal cell cancers and implications for targeted therapy [abstract]. The Journal of Urology. 2012; 187 ( 4 ): e183 – e184.en_US
dc.identifier.citedreferenceArgani P, Ladanyi M. Translocation carcinomas of the kidney. Clin Lab Med. 2005; 25: 363 ‐ 378.en_US
dc.identifier.citedreferenceArgani P, Antonescu CR, Illei PB, et al. Primary renal neoplasms with the ASPL‐TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol. 2001; 159: 179 ‐ 192.en_US
dc.identifier.citedreferencePerot C, Boccon‐Gibod L, Bouvier R, et al. Five new cases of juvenile renal cell carcinoma with translocations involving Xp11.2: a cytogenetic and morphologic study. Cancer Genet Cytogenet. 2003; 143: 93 ‐ 99.en_US
dc.identifier.citedreferenceKuiper RP, Schepens M, Thijssen J, et al. Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)‐positive renal cell carcinomas due to promoter substitution. Hum Mol Genet. 2003; 12: 1661 ‐ 1669.en_US
dc.identifier.citedreferenceArgani P, Lal P, Hutchinson B, Lui MY, et al. Aberrant nuclear immunoreactivity for TFE3 and neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003; 27: 750 ‐ 761.en_US
dc.identifier.citedreferenceArgani P, Lae M, Hutchinson B, et al. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha‐TFEB gene fusion by immunohistochemistry, RT‐PCR, and DNA PCR. Am J Surg Pathol. 2005; 29: 230 ‐ 240.en_US
dc.identifier.citedreferenceRamphal R, Pappo A, Zielenska M, et al. Pediatric renal cell carcinoma: clinical, pathologic, and molecular abnormalities associated with the members of the Mit transcription factor family. Am J Clin Pathol. 2006; 126: 349 ‐ 364.en_US
dc.identifier.citedreferenceArgani P. The evolving story of renal translocation carcinoma. Am J Clin Pathol 2006; 126: 332 ‐ 334.en_US
dc.identifier.citedreferencePeloni AM, Dobbs RM, Pontes JE, et al. Translocation (X;1) in papillary renal cell carcinoma. A new cytogenetic subtype. Cancer Genet Cytogenet. 1993; 65: 1 ‐ 6.en_US
dc.identifier.citedreferenceTomlinson GE, Niesen PD, Timmons CF, et al. Cytogenetics of a renal cell carcinoma in a 17‐month‐old child. Evidence for Xp11.2 as a recurring breakpoint. Cancer Genet Cytogenet. 1991; 57: 11 ‐ 17.en_US
dc.identifier.citedreferenceSidhar SK, Clark J, Gill S, et al. The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet. 1996; 5: 1333 ‐ 1338.en_US
dc.identifier.citedreferenceWeterman MA, Wilbrink M, Geurts van Kessel A. Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)‐positive papillary renal cell carcinomas. Proc Natl Acad Sci U S A. 1996; 93: 15294 ‐ 15298.en_US
dc.identifier.citedreferenceArgani P, Hawkins A, Griffin CA, et al. A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11) (p21.1;q12) chromosome translocation. Am J Pathol. 2001; 158: 2089 ‐ 2096.en_US
dc.identifier.citedreferenceKlatte T, Streubel B, Wrba F, et al. Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis. Am J Clin Pathol. 2012; 137: 761 ‐ 768.en_US
dc.identifier.citedreferenceMacher‐Goeppinger S, Roth W, Wagener N, et al. Molecular heterogeneity of TFE3 activation in renal cell carcinomas. Mod Pathol. 2012; 25: 308 ‐ 315.en_US
dc.identifier.citedreferenceCamparo P, Vasiliu V, Molinie V, et al. Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol. 2008; 35: 656 ‐ 670.en_US
dc.identifier.citedreferenceMeyer PN, Clark JI, Flanigan RC, et al. Xp11.2 translocation renal cell carcinoma with very aggressive course in 5 adults. Am J Clin Pathol. 2007; 128: 70 ‐ 79.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr29368.pdf
Size:
114.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.